3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Breast Neoplasms
59
Colorectal Neoplasms
45
Rectal Neoplasms
35
Stomach Neoplasms
27
Pancreatic Neoplasms
27
Neoplasm Metastasis
24
Neoplasms
19
Colonic Neoplasms
18
Triple Negative Breast Neoplasms
7
Esophageal Neoplasms
6
Adenocarcinoma
6
Liver Neoplasms
5
Brain Neoplasms
5
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms, Unknown Primary
2
Melanoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Squamous Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Interventions
Doxorubicin
13
Gemcitabine
10
Cyclophosphamide
10
pazopanib
8
Filgrastim
8
Radiotherapy
7
Ifosfamide
7
Cisplatin
7
Irinotecan
6
Docetaxel
6
Radiation
5
Granulocyte Colony-Stimulating Factor
5
Etoposide
5
Trabectedin
4
Magnetic Resonance Spectroscopy
4
Celecoxib
4
Busulfan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
sargramostim
3
pembrolizumab
3
X-Rays
3
Sirolimus
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Neoadjuvant Therapy
3
Leucovorin
3
Dexrazoxane
3
Cryosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma
×
Capecitabine
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts